El Segundo, CA, September 30, 2016 – BioDiscovery, Inc. a leader in integrated software solutions for genomics data analysis for life sciences, will be launching NxClinical 3.0 at the upcoming American Association of Human Genetics (ASHG) Annual Meeting in Vancouver. NxClinical 3.0 is a flexible, platform-agnostic database solution for efficient analysis, interpretation, and reporting of copy number and sequence variants as well as AOH.
“We are really excited about the upcoming release of NxClinical 3.0 and its unique position in the market as the only product that combines data from arrays and NGS in one database,” said Dr. Soheil Shams, President, BioDiscovery, Inc. “We have customers who have been using NxClinical for CNV and AOH interpretation and reporting and are now moving into next-generation sequencing platforms. They are extremely thrilled to know that they can continue with the same reliable software as they expand their labs.”
NxClinical 3.0 will be launched during the American Society of Human Genetics (ASHG) 2016 Meeting, October 18-21 in Vancouver, BC, Canada. Conference attendees have the opportunity to visit BioDiscovery at booth #1419 to get a demo of NxClinical 3.0. BioDiscovery will also be introducing NxClinical 3.0 at a lunchtime ancillary event:
Title: Still using multiple systems for NGS and array data? STOP! Unite them with NxClinical 3.0
Date: Wednesday, October 19, 2016
Time: 1:00pm - 2:30pm
Location: Convention Center, Ballroom B, East Building
To register for ASHG events or learn more about NxClinical 3.0, please visit our website.
BioDiscovery’s NxClinical software increases accuracy and efficiency in molecular genetics and cytogenomics labs’ workflows. NxClinical’s platform-independence allows labs to use the same software for analysis and interpretation of data from any technology (e.g. aCGH arrays, SNP arrays, and NGS) allowing much greater flexibility and ease in adopting the best technology for a lab without having to invest additional time and money in installation, training, and validation with a new system. The automated workflows can be customized to mirror a lab’s decision making process and classification terms to pre-classify events, removing repetitive tasks and minimizing potential human error. The system allows enforcement of lab SOPs with assigned user roles and privileges for appropriate user access, extensive audit trail capabilities, and flexible deployment with local or cloud-based options.
About BioDiscovery, Inc.
BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. The company’s mission is to enable scientists to eliminate disease and suffering through application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the genomics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. BioDiscovery’s passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system enabling research findings to translate into clinical applications and make direct impact on patient care. For more information, visit http://www.biodiscovery.com.
Please note the following:
The BioDiscovery software tools referenced are designed to assist clinical researchers and are not intended as primary diagnostic tools. It is each lab’s responsibility to use the software in accordance with internal policies as well as in compliance with applicable regulations.